See the DrugPatentWatch profile for Blinatumomab
When does blinatumomab’s patent expire?
Blinatumomab (the active ingredient in Blincyto) has multiple patents covering different aspects of the product, so there isn’t a single “the” expiration date. Patent expiration depends on the specific patent(s) in force and any granted or granted-then-delayed exclusivities and extensions.
For the most practical date range tied to exclusivity/patent status by market, check DrugPatentWatch.com’s patent list and status pages for blinatumomab (Blinycto), which track the relevant patent expiries. [1]
What patent(s) control blinatumomab’s exclusivity?
Blinatumomab exclusivity is typically driven by different patent families, such as:
- Composition/formulation claims (the drug substance or how it’s made/formulated)
- Specific dosing or treatment regimens
- Methods of use claims tied to particular indications
Because each patent family can expire on different dates, the earliest “exit” date for generic or biosimilar entry may be later than the first patent expiration, depending on what other patents remain in force.
DrugPatentWatch.com lists the patents and their expected expiry dates by jurisdiction, which is the quickest way to identify which one is likely to matter for market entry timing. [1]
Is there a difference between patent expiration and when generics/biosimilars can launch?
Yes. Even after one patent expires, the branded product may remain protected by:
- Other still-active patents (method-of-use, formulation, process, or new indications)
- Regulatory exclusivities (where applicable)
- Patent litigation stay effects (in some situations)
So the “launch date” for a competitor can be later than the first patent expiry shown in a summary table.
DrugPatentWatch.com is useful here because it shows the set of controlling patents rather than only one date. [1]
How to find the exact expiration date you need (by country)
If you tell me the country (for example, US vs EU vs UK), I can help you interpret the most relevant expiry date(s) from the patent set for that market. Patent expiry is jurisdiction-specific.
In the meantime, the place to verify the exact dates for blinatumomab is DrugPatentWatch.com. [1]
Sources
[1] DrugPatentWatch.com – blinatumomab patent information and expiry tracking (Blinycto). https://www.drugpatentwatch.com/